The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema

Expert Opinion on Investigational Drugs

Volumn 15, Issue 9, 2006, Pages 1077-1090

  Levy, Jerrold H ^a   O'Donnell, Penrose S ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b Dyax Corp   (United States)

Author keywords

Acquired angioedema; Bradykinin; C1 inhibitor; DX 88; Hereditary angioedema; Kallikrein; Kinin

Indexed keywords

ADRENALIN; AMINOCAPROIC ACID; ANDROGEN; ANTIHISTAMINIC AGENT; BLOOD DERIVATIVE; BRADYKININ; CAPTOPRIL; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DX 88; ECALLANTIDE; ESTROGEN; ETHYLTESTOSTERONE; FRESH FROZEN PLASMA; ICATIBANT; INFUSION FLUID; KALLIKREIN; KALLIKREIN INHIBITOR; KININ; LIVER ENZYME; OMAPATRILAT; PLACEBO; RECOMBINANT COMPLEMENT COMPONENT C1S INHIBITOR; STANOZOLOL; STEROID; THROMBOPLASTIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VASOPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; AUTOSOMAL DOMINANT INHERITANCE; BLOOD CLOTTING DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG MECHANISM; ENZYME DEFECT; EUROPE; FATIGUE; GASTROINTESTINAL TRACT; GENETIC DISORDER; HIRSUTISM; HUMAN; HYPOTENSION; KALLIKREIN KININ SYSTEM; LARYNX; LIMB; LIVER CELL CARCINOMA; META ANALYSIS; MUSCLE WEAKNESS; MYALGIA; NAUSEA AND VOMITING; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS; REVIEW; RHABDOMYOLYSIS; SUBMUCOSA; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; UNITED STATES; WEIGHT GAIN;

ANGIOEDEMA; ANGIONEUROTIC EDEMA; ANIMALS; DISEASE SUSCEPTIBILITY; ENZYME INHIBITORS; HUMANS; KALLIKREINS; KININS; PEPTIDES;

EID: 33748149553     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.9.1077     Document Type: Review

References (95)

1. BOWEN T, CICARDI M, FARKAS H et al.: Canadian 2003 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. J Allergy Clin. Immunol. (2004) 114:629-637.
2. AGOSTONI A, AYGORFN-PURSUN E, BINKLEY KE et al.: Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. (2004) 114:S51-131.
3. CICARDI M, BERGAMASCHINI L, CUGNO M et al.: Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology (1998) 199:366-376.
4. BORK K, HARDT J, SCHICKETANZ KH, RESSEL N: Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch. Intern. Med. (2003) 163:1229-1235.
5. ROCHE O, BLANCH A, CABALLERO T et al.: Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann. Allergy Asthma Immunol. (2005) 94:498-503.
6. FRANK MM: Urticaria and angioedema. In: Goldman: Cecil textbook of medicine. Goldman L, Ausiello D (Eds), WB Saunders Co., Philadelphia, USA (2004) 22:1613.
7. TOSI M: Molecular genetics of C1 inhibitor. Immunobiology (1998) 199:358-365.
8. DAVIS AE: C1 inhibitor and hereditary angioneurotic edema. Ann. Rev. Immunol. (1988) 6:595-628.
9. AGOSTONI A, CICARDI M: Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (1992) 71:206-215.
10. BRICKMAN CM, TSOKOS GC, CHUSED TM et al.: Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. J. Allergy Clin. Immunol. (1986) 77:758.
11. DAVIS AE: The pathophysiology of hereditary angioedema. Clin. Immunol. (2005) 114:3-9.
12. LEHMANN A: Ecallantide. Curr. Opin. Invest. Drugs (2006) 7(3):282-290.
13. WILLIAMS A, BAIRD LG: DX-88 and HAE: a developmental perspective. Transfus. Apher. Sci. (2003) 29:255-258.
14. WILLIAMS T, SCHNEIDER L, LUMRY W, VEGH A: DX-88: a double blind placebo controlled study in hereditary angioedema (HAE) the EDEMAI study. 2004 Annual Meeting of the American College of Allergy, Asthma and Immunology, Boston, USA (2004):38.
15. SILVERBERG M, REDDIGARI SR, KAPLAN AP: The contact system and its disorders. In: Blood: Principles & Practice of Hematology. Handin RI, Lux SE, Stossel RP (Eds), JB Lippincott Co., Philadelphia, USA (1995):1127-1150.
16. GREAVES M, LAWLOR F: Angioedema: manifestations and management. J. Am. Acad. Derm. (1991) 25:155-161.
17. BORK K, RISCHER B, DEWALD G: Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am. J. Med. (2003) 114:294-298.
18. MALBRAN A, HAMMER CH, FRANK MM, FRIES LF: Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J. Allergy Clin. Immunol. (1998) 81:1199-1204.
19. VLEEMING W, VAN AMSTERDAN JG, STRICKER BH, DE WILDT DJ: ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. (1998) 18:171-88.
20. PAVLETIC A: Late angioedema caused by ACE Inhibitors underestimated. Am. Fam. Physician (2002) 66:956-958.
21. MOLINARO G, CUGNO M, PEREZ M et al.: Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J. Pharmacol. Exp. Ther. (2002) 303:232-237.
22. ZANCHI A, MAILLARD M, BURNIER M: Recent clinical trials with omapatrilat: new developments. Curr. Hypertens. Rep. (2003) 5:346-352.
23. SIM RB, ARLAUD GJ, COLOMB MG: C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes. Biochem. J. (1979) 179(3):449-457.
24. OLTVAI ZN, WONG ECC, ATKINSON JP, TUNG KS: C1 inhibitor deficiency: molecular and immunologic basis of hereditary and acquired angioedema. Lab. Invest. (1991) 65:381-388.
25. DAVIS AE: The pathogenesis of hereditary angioedema. Transfus. Apher. Sci. (2003) 29:195-203.
26. PETERSEN SV, THIEL S, JENSEN L, VORUP-JENSEN T, KOACH C, JENSENIUS JC: Control of the classical and the MBL pathway of complement activation. Mol. Immunol. (2000) 37(14):803-811.
27. JIANG H, WAGNER E, ZHANG H, FRANK MM: Complement 1 inhibitor is a regulator of the alternative complement pathway. J. Exp. Med. (2001) 194(11):1609-1616.
28. ZICCARDI RJ: Activation of the early components of the classical complement pathway under physiologic conditions. J. Immunol. (1981) 126:1769-1773.
29. DE AGOSTINI A, LIJNEN HR, PIXLEY RA, COLMAN RW, SCHAPIRA M: Inactivation of factor-XII active fragment in normal plasma: predominant role of C1-inhibitor. J. Clin. Invest. (1984) 73(6):1542-1549.
30. SHAPIRA M, SCOTT CF, COLMAN RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. (1992) 69:462-468.
31. VAN DER GRAAF F, KOEDAM JA BOUMA BN: Inactivation of kallikrein in human plasma. J. Clin. Invest. (1983) 71:149-158.
32. SHARIAT-MADAR Z, MAHDI F, SCHMAIER AH: Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekailikrein activator. J. Biol. Chem. (2002) 277:17962.
33. JOSEPH K, KAPLAN AP: Formation of bradykinin: a major contributor to the innate inflammatory response. Adv. Immunol. (2005) 86:159-208.
34. BAUER K: Hypercoagulable states. In: Hematology. basic principles and practice. Hoffman R (Ed.), Churchill Livingstone, Philadelphia, USA (2005) 4:2209.
35. CYR M, LEPAGE Y, BLAIS C et al.: Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation in human plasma. Am. J. Physiol. Heart Circ. Physiol. (2001) 281:H275-H283.
36. KAPLAN AP, GHEBREHIWET B: Does C-2 kinin exist? J. Allergy Clin. Immunol. (2005) 115:876.
37. ZAHEDI R, BISSLER JJ, DAVIS AE, ANDREADIS C, WISNIESKI JJ: Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-Val substitution and functional analysis of the recombinant mutant protein. J. Clin. Invest. (1995) 95:1299-1305.
38. JUHLIN L, MICHAELSSON G: Vascular reactions in hereditary angioedema. Acta Derm. Venereal. (1969) 49:20.
39. CURD JG, YELVINGTON M, BURRIDGE N et al.: Generation of bradykinin during incubation of hereditary angioedema plasma. Mol. Immunol. (1982) 19:1365.
40. CURD JG, PROGRAIS LJ, COCHRANE CG: Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J. Exp. Med. (1980) 152:742-747.
41. FIELDS T, GHEBREWIHET B, KAPLAN A: Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of spontaneous formation of bradykinin. J. Allergy Clin. Immunol. (1983) 72:54-60.
42. SHOEMAKER LR, SCHURMAN SJ, DONALDSON VH, DAVIS AE: Hereditary angioneurotic edema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin. Exp. Immunol. (1994) 95:22-28.
43. CUGNO M, NUSSBERGER J, CICARDI M, AGOSTONI A: Bradykinin and the pathophysiology of angioedema. Inter. Immunopharm. (2003) 3(3):311-317.
44. NUSSBERGER J, CUGNO M, AMSTUTZ C et al.: Plasma bradykinin in angioedema. Lancet (1998) 351:1693-1697.
45. NUSSBERGER J, CUGNO M, CICARDI M: Bradykinin-mediated angioedema. N. Engl. J..Med. (2002) 347:621-622.
46. NUSSBERGER J, CUGNO M, CICARDI M, AGOSTONI A: Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. (1999) 104(6):1321-1322.
47. HAN ED, MacFARLANE RC, MULLIGAN AN, SCAFIDI J, DAVIS AE: Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Invest. (2002) 109(8):1057-1063.
48. CICARDI M, AGOSTONI A: Hereditary angioedema. N. Engl. J. Med. (1996) 334:1666-1667.
49. LONGHURST HJ: Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int. J. Clin. Pract. (2005) 59:594-599.
50. WINNEWISSER J, ROSSI M, SPATH P, BURGI H: Type I hereditary angio-edema. Variability of clinical presentation and course within two large kindreds. J. Intern. Med. (1997) 241(1)39-46.
51. GOMPELS MM, LOCK RJ, ABINUN M et al.: C1 Inhibitor deficiency: consensus document. Clin. Exp. Immunol. (2005) 139(3):379-394.
52. SIM TC, GRANT JA: Hereditary angioedema: its diagnostic and management perspectives. Am. J. Med. (1990) 88(6):656-664.
53. GELFAND JA, SHERINS RJ, ALLING DW, FRANK MM: Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N. Engl. J. Med. (1976) 295(26):1444-1448.
54. GADEK JE, HOSEA SW, GELEAND JA, FRANK MM: Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. J. Clin. Invest. (1979) 64(1):280-286.
55. CICARDI M, CASTELLI R, ZINGALE LC, AGOSTONI A: Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J. Allergy Clin. Immunol, (1997) 99(2):194-196.
56. BORK K, PITTON M, HARTEN P, KOCH P: Hepatocellular adenomas in patients taking danazol for hereditary angio-edema. Lancet (1999) 353(9158):1066-1067.
57. RITCHIE BC: Protease inhibitors in the treatment of hereditary angioedema. Transfus. Apher. Sci. (2003) 29(3):259-267.
58. WALLACE EM, PERKINS SJ, SIM RB, WILLIS AC, FEIGHERY C, JACKSON J: Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes. Mol. Med. (1997) 3:385-396.
59. FRANK MM, SERGENT JS, KANE MA, ALLING DW: Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double blind study. N. Engl. J. Med. (1976) 295:1444-1448.
60. CICARDI M, ZINGALE L: How do we treat patients with hereditary angioedema. Transfus. Apher. Sci. (2003) 29(3):221-227.
61. ZURAW BL: Diagnosis and management of hereditary angioedema: an American approach. Transfus. Apher Sci. (2003) 29(3):239-245.
62. BORK K, WITZKE G: Long term prophylaxis with C1-inhibitor concentrate with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J. Allergy Clin. Immunol. (1989) 83:677-682.
63. BORK K, MENG G, STAUBACH P, HARDT J: Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion (2005) 45:1774-1784.
64. LONGHURST HJ: Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int. J. Clin. Pract. (2005) 59:594-599.
65. GADEK JE, HOSEA SW, GELFAND JA et al.: Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N. Engl. J. Med. (1980) 302:542-546.
66. DE SERRES J, GRONER A, LINDNER J: Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus. Apher. Sci. (2003) 29:247-254.
67. WAYTES AT, ROSEN FS, FRANK MM: Treatment of hereditary angioedema with a vapor-heated C1 Inhibitor concentrate. N. Engl. J. Med. (1996) 334:1630-1634.
68. KUNSCHAK M, ENGL W, MARITSCH F et al.: A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion (1998) 38(6):540-549.
69. BERGAMASCHINI L, CICARDI M: Recent advances in the use of C1 inhibitor as a therapeutic agent. Mol. Immunol. (2003) 40:155-158.
70. FRANK M: Hereditary angioedema: a half century of progress. J. Allergy Clin. Immunol. (2004) 114:626-628.
71. MARKLAND W, LEY AC, LADNER RC: Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry (1996) 35(24):8058-8067.
72. LEY AC, MARKLAND W, LADNER RC: Obtaining a family of high-affinity, high specificity protein inhibitors of plasmin and plasma kallikrein. Mol. Divers. (1996) 2:119-124.
73. NIXON AE: Use of phage display to identify potent and specific protease inhibitors. 18th American Peptide Symposium on Peptide Revolution: Genomics, Proteomics and Therapeutics, Boston, USA (2003):0719.
74. SEXTON D: DX-88 protease specificity measurements. Version 1. Unpublished Dyax internal data, on file (2006).
75. WIMAN B: Human C1-inhibitor. In: Proteinase Inhibitors. Barrett AJ, Salvesen G (Eds), Elsevier, New York, USA (1990):477-488.
76. PIXLEY RA, SCHAPIRA M, COLMAN RW. The regulation of human Factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. (1985) 260:1723-1729.
77. WIMAN B, NILSSON T: kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s. Eur. J. Biochem. (1983) 129:663-667.
78. SCHAPIRA M, SCOTT CF, COLMAN RW: Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry (1981) 20(10):2738-2743.
79. WUILLEMIN WA, ELDERING E, CITARELLA F, DE RUIG CP, CATE H, HACK CE: Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J. Biol. Chem. (1996) 271(22):12913-12918.
80. GUNAWARDENA K: An open-label study of the pharmacokinetic and safety profiles of subcutaneous versus intravenous formulations of ecallantide (DX-88), a potent recombinant protein inhibitor of human plasma kallikrein. Annual Meeting of the American College of Asthma, Allergy, and Immunology, Anaheim, USA (2005) (Booth 1029).
81. IAN J, LAWRIE AS, PURDY G, WILLIAMS T, MACHIN SJ: DX-88, a novel kunitz-type inhibitor of human plasma kallikrein with potential therapeutic use. 44th Annual Meeting of the American Society of Hematology, Philadelphia, USA (2002):3892 (Abstract).
82. CICARDI M, GONZALEZ-QUEVEDO T, CABALLERO T, BORK K, WILLIAMS A: DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema. 9th European Complement Workshop, Trieste, Italy (2003):0906.
83. GONZALEZ-QUEVEDO T, CICARDI M, BORK K, WILLIAMS A: The synthetic Kunitz domain protein DX88 to treat angioedema in patients with hereditary angioedema. XIX International Complement Workshop, Palermo, Italy (2002):0922.
84. WILLIAMS T, CICARDI M, BORK K, GONZALEZ-QUEVEDO T, CABELLERO T: DX-98, a recombinant inhibitor of human plasma kallikrein. Evaluation of efficacy and safety in patients with hereditary angioedema. 60th Aniversary Meeting of the American Academy of Allergy, Asthma and Immunology, Denver, USA (2003):L3.
85. DEVERAS RA, BRACHO F: Inhibitor of human plasma kallikrein DX-88 for the treatment of acute attack in a family with hereditary angioedema. 46th Annual Meeting of the American Society of Hematology, San Diego, USA (2004):4109.
86. LUMRY W, RITCHIE B, BECK T, MORRISON J: Interim results of EDEMA2, a multicenter, open-label, repeat dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema. J. Allergy Clin. Immunol. (2006) 117(2S):S179 (Abstract).
87. LI HH, SCHNEIDER L, CRAIG T, LUMRY W, BECK T. Repeat dosing of IV and SC formulations of DX-88, a highly potent inhibitor of human plasma kallikrein for the treatment of patients with hereditary angioedema. XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, Austria (2006) (In Press).
88. POLK RE: Anaphylactoid reactions to gylcopeptide antibiotics. J. Antimicrob. Chemother. (1991) 27(Suppl. B):17-29.
89. LEVY M, KOREN G, DUPUIS L, READ SE: Vancomycin-induced red man syndrome. Pediatrics (1990) 86(4):572-580.
90. LIEBE V, BRUCKMANN M, FISCHER KG, HAASE KK, BORGGREFE M, HUHLE G: Biological relevance of anti-recombinant hirudin antibodies - results from in vitro and in vivo studies. Semin. Thromb. Hemost. (2002) 28(5):483-490.
91. 1a. J. Interferon Cytokine Res. (1998) 18:345-350.
92. CABALLERO T, LOPEZ-SERRANO C: Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J. Allergy Clin. Immunol. (2006) 117(2):476-477.
93. WILLIAMS, T. DX-88, a novel recombinant protein inhibitor of plasma kallikrein: safety and immunogenicity in early studies. J. Allergy Clin. Immunol. (2005) 115:S181 (Abstract).
94. BECK TR, BAIRD LG: Reply to: Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J. Allergy Clin. Immunol. (2006) 117(2):477.
95. MacKIE I: DX-88 specificity and effects on activated contact factors. Unpublished Dyax internal data, on file (2005).